12 December 1997
Ann Transplant 1997; 2(4): 42-48 :: ID: 497340
Post-transplant Iymphoproliferative diseases (PTLDs) are a clinically and morphologically heterogeneous group of lymphoid proliferations. They represent a life-threatening complication of solid organ transplantation. The mechanisms of their pathogenesis are not yet fully understood. A combination of impaired immunity, oncogenic consequences of immunosuppressive therapy and EBV infection may playa role. Studies on incidence, treatment and prognosis are difficult because of the small number of cases occurring at each transplant center and the lack of reliable classification. Overall mortality remains high even though 25% of patients require no other measure than reduction in immunosuppression which must be the first step of treatment. Several treatments are currently used but more adequate classification as well as multicenter studies are urgently needed because many questions remain with regard to therapeutic strategy. Late-onset monoclonal tumors may be treated by conventional chemotherapy, while EBV-positive PTLDs may benefit from other approaches such as antiviral therapies or immunologic modulation of tumor functions.
Keywords: post-transplant Iymphoproliferative disease, Epstein-Barrvirus
12 Feb 2024 : Original articleNo Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...
Ann Transplant In Press; DOI: 10.12659/AOT.942767
Most Viewed Current Articles
05 Apr 2022 : Original articleImpact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original articleRisk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original articleLong-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...
Ann Transplant 2022; 27:e937988